Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade

• DOI: 10.1073/pnas.1905005116
• Publication Date: 2019-08-02T22:55:15Z
• Authors: Mohammad Rashidian; Martin W. LaFleur; Vincent L. Verschoor; Anushka Dongre; Yun Zhang; Thao H. Nguyen; Stephen Kolifrath; Amir R. Aref; Christie J. Lau; Cloud P. Paweletz; Xia Bu; Gordon J. Freeman; M. Inmaculada Bar...; Robert A. Weinberg; Arlene H. Sharpe; Hidde L. Ploegh
• Keywords: 0301 basic medicine; CD11b Antigen; Programmed Cell Death 1 Receptor; Neoplasms, Experimental; Adenocarcinoma; CD8-Positive T-Lymphocytes; Neoplasm Proteins; 3. Good health; Mice; 03 medical and health sciences; Antigens, Neoplasm; Cell Line, Tumor; Positron-Emission Tomography; Tumor Microenvironment; Animals; Female; Colorectal Neoplasms

Significance

Immunotherapy, especially blockade of the PD-1/PD-L1 and CTLA-4 axes, has resulted in durable responses in a range of cancers. However, responses remain heterogeneous among patients. Treatment outcome results from changes in the tumor microenvironment imposed by such blockade. Here, we use immuno-PET and single-cell RNA sequencing to increase our understanding of the dynamics of immune cells and their functional status in the tumor microenvironment in response to PD-1 blockade. Our data provide insights into the dynamics of CD8 + T cells and the functional status of the myeloid compartment in response to PD-1 blockade.